SpringerLink
Log in

Beneficial effects of romosozumab on bone mineral density and trabecular bone score assessed by dual-energy X-ray absorptiometry in a family with osteogenesis imperfecta

  • Letter to the Editor
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The datasets used and analyzed in this report are available from the corresponding author upon reasonable request.

References

  1. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952

    Article  CAS  PubMed  Google Scholar 

  2. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tato L (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126–130

    Article  CAS  PubMed  Google Scholar 

  3. Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, Russell RG, Brown MA, Duncan EL (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 23:285–294

    Article  CAS  PubMed  Google Scholar 

  4. Kitamura T, Ishihara Y, Kusakabe T, Tsuiki M, Nanba K, Hiroshima-Hamanaka K, Nomura T, Satoh-Asahara N, Yasoda A, Tagami T (2023) A case of osteogenesis imperfecta caused by a COL1A1 variant, coexisting with pituitary stalk interruption syndrome. Endocr J 70:839–846

    Article  PubMed  Google Scholar 

  5. Ohata Y, Kitaoka T, Ishimi T et al (2023) Association of trabecular bone score and bone mineral apparent density with the severity of bone fragility in children and adolescents with osteogenesis imperfecta: A cross-sectional study. PLoS ONE 18:e0290812

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Uehara M, Nakamura Y, Nakano M, Miyazaki A, Suzuki T, Takahashi J (2022) Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: a case report. Modern rheumatology case reports 6:128–133

    Article  PubMed  Google Scholar 

  7. Dattagupta A, Petak S (2023) Osteoporosis improved by romosozumab therapy in a patient with type I osteogenesis imperfecta. AACE clinical case reports 9:209–212

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hong N, Shin S, Lee S, Rhee Y (2023) Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis. Osteoporos Int 34:2059–2067

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Hiromi Kusakabe and Sayo Hasegawa at the National Hospital Organization Kyoto Medical Center for their secretarial assistance and their assistance in acquiring the data.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization (NHO) Kyoto Medical Center, Kyoto, Japan

    Toru Kusakabe, Yuki Ishihara, Takuya Kitamura, Kazutaka Nanba, Noriko Satoh-Asahara & Tetsuya Tagami

  2. Department of Endocrinology and Metabolism, National Hospital Organization (NHO) Kyoto Medical Center, Kyoto, Japan

    Yuki Ishihara, Takuya Kitamura, Kazutaka Nanba, Mika Tsuiki & Tetsuya Tagami

  3. Clinical Research Institute, National Hospital Organization (NHO) Kyoto Medical Center, Kyoto, Japan

    Akihiro Yasoda & Mika Tsuiki

Authors
  1. Toru Kusakabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuki Ishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takuya Kitamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akihiro Yasoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazutaka Nanba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mika Tsuiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Noriko Satoh-Asahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tetsuya Tagami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toru Kusakabe.

Ethics declarations

Ethics approval

The letter to the Editor was conducted according to the ethical standards of the Declaration of Helsinki.

Patient consent.

We obtained written consent from the patients to publish this report.

Conflicts of interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kusakabe, T., Ishihara, Y., Kitamura, T. et al. Beneficial effects of romosozumab on bone mineral density and trabecular bone score assessed by dual-energy X-ray absorptiometry in a family with osteogenesis imperfecta. Osteoporos Int 35, 1303–1304 (2024). https://doi.org/10.1007/s00198-024-07089-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-024-07089-2

Search

Navigation